All In Biotech

Drug Trial Radar · NCT07205718

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

An Open-label, Dose Escalation and Expansion, Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TAK- 188, an Anti-CCR8 Antibody-Drug- Conjugate, as a Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

273

Planned (sponsor's estimate)

Start

Nov 19, 2025

Primary completion

Dec 26, 2028

Study completion Dec 21, 2029

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Oct 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 may help to remove these Tregs. Removing these Tregs may allow more cancer-fighting cells (CD8+ T cells) to attack the tumor and potentially stop tumors from growing. In this study, researchers want to learn if TAK-188 can help the body's immune system better fight cancer in adults with advanced cancers which have not gotten better with regular treatments. The main aims of this study are to check if TAK-188 is safe in adults with advanced or spreading (metastatic) solid tumors, if participants tolerate the treatment with TAK-188 and to learn if TAK-188 works well in adults with certain advanced cancers after their previous treatments didn't work. Participants may receive TAK-188 for up to 1 year. Their health will be monitored after the treatment has ended for up to another year.

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

  • TAK-188Drug

    TAK-188 IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: From the signing of the informed consent form (ICF) through 90 days after the last dose (Up to approximately 16 months)
  2. Phase 1: Number of Participants with TEAEs Based on SeverityTime frame: From the signing of the ICF through 90 days after the last dose (Up to approximately 16 months)
  3. Phase 1: Number of Participants with Dose- limiting Toxicities (DLTs)Time frame: Up to Cycle 1 (21 days)
  4. Phase 1: Number of Participants with Treatment-emergent Serious Adverse Events (SAEs)Time frame: From the signing of the ICF through 90 days after the last dose (Up to approximately 16 months)
  5. Phase 1: Number of Participants with Treatment-emergent Adverse Events Leading to Dose Modifications and Treatment DiscontinuationsTime frame: From the signing of the ICF through 90 days after the last dose (Up to approximately 16 months)
  6. Phase 1b Backfill and Phase 2 Dose Expansion and Optimization: Overall Response Rate (ORR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Up to 24 months
  7. Phase 1b Backfill and Phase 2 Dose Expansion and Optimization: Disease Control Rate (DCR)Time frame: Up to 24 months
  8. Phase 1b Backfill and Phase 2 Dose Expansion and Optimization: Duration of Response (DOR)Time frame: Up to 24 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA Health-Santa Monica Cancer Care (Cancer Care - Santa Monica)

    Santa Monica, California · Recruiting

  • Yale School of Medicine - Smilow Cancer Hospital - Center for Thoracic Cancers

    New Haven, Connecticut · Recruiting

  • Florida Cancer Specialists - Lake Nona

    Orlando, Florida · Recruiting

  • Johns Hopkins

    Baltimore, Maryland · Recruiting

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Providence Cancer Institute, Franz Clinic

    Portland, Oregon · Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • SCRI Oncology

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Dallas

    Irving, Texas · Recruiting

  • START San Antonio

    San Antonio, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.